JAMA Health Forum
November 1, 2024
Otto Simonsson, Matthew W. Johnson, Peter S. Hendricks
10 citations
This Viewpoint discusses the need to better understand potential risks associated with psychedelic and 3,4-methylenedioxymethamphetamine (MDMA) use to ensure safe and ethical practice and identifies 4 key research goals.
European Child & Adolescent Psychiatry
November 1, 2024
Samuli Kangaslampi, Josjan Zijlmans
18 citations
3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may be approved for adults soon. PTSD is also common among trauma-exposed adolescents, and current treatments leave much room for improvement. We present a rationale for considering MDMA-AP for treating PTSD among adolescents. Evidence suggests that as an...
Drug and Alcohol Dependence
November 1, 2024
Eric L Sevigny, Sylvia Thyssen, Earth Erowid et al.
5 citations
The misrepresentation of illicit drugs in unregulated markets increases the risk of adverse health events. This study analyzed drug checking data to compare represented, expected, and actual content of alleged MDMA samples, estimate trends in the quality of the MDMA supply, document the presence of adulterants, compare patterns of adulteration, and validate drug checking against law enforcement...
AJN, American Journal of Nursing
November 1, 2024
Karen Roush
The agency cited potential dangers and flaws in research methodology.
Asian Journal of Psychiatry
November 1, 2024
Zifan Zhen, Xueqiang Sun, Shiying Yuan et al.
8 citations
In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as hallucinogens, 3,4-methylenedioxymethamphetamine (MDMA), and ketamine for the treatment of severe mental health disorders. This review provides a detailed evaluation of these substances, focusing on their mechanisms of action and the profound...
Journal of Psychoactive Drugs
October 23, 2024
Jessica L Maples-Keller, Courtland S Hyatt, Nathaniel L Phillips et al.
2 citations
3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research suggests a change in personality traits may be a factor in treatment response. Most prior research on MDMA and personality has focused on cross-sectional comparisons of MDMA users and non-users; as such, well-controlled research assessing personality and...
Revista Sociedade Científica
October 22, 2024
Manuela Bahia Almeida da Franca, Sandra Regina Mota Ortiz
O Transtorno do Estresse Pós-Traumático (TEPT) é caracterizado por um conjunto de sinais e sintomas associados a um profundo sofrimento psicológico após a vivência ou testemunha de um episódio traumático. Apesar de muito prevalente na população, a abordagem atual do transtorno possui importantes limitações, o que afeta de maneira significativa a qualidade de vida dos afetados. Diante desse...
bioRxiv : the preprint server for biology
October 22, 2024
Matthew B Pomrenze, Sam Vaillancourt, Juliana S Salgado et al.
1 citation
preprint
MDMA is a promising adjunct to psychotherapy and has well-known abuse liability, although less than other amphetamine analogs. While the reinforcing dopamine (DA)-releasing properties of MDMA are on par with methamphetamine (METH), MDMA is a far more potent serotonin (5-HT) releaser, via the 5-HT transporter (SERT). MDMA-mediated 5-HT release in a major reward center, the nucleus accumbens...
Revista Eletrônica Acervo Saúde
October 18, 2024
Lucas Siqueira Dos Santos, João Marcos Santos Oliveira, Layane Estefany Siqueira Dos Santos
Objetivo: Analisar as consequências para a saúde mental provocadas pelo consumo do Dietilamida do Ácido Lisérgico (LSD) e metilenodioximetanfetamina (MDMA) por jovens e adolescentes. Revisão bibliográfica: Este artigo promove uma discussão e análise acerca do consumo desenfreado de LSD e MDMA por jovens e adolescentes. O crescimento exponencial do mercado ilegal do tráfico de drogas e a criação...
HAL
October 12, 2024
Philippe Rochat
preprint
A universal aspect of human psychology is the quest and cultivation of rapture states, the need to stand outside oneself (ecstasy). The question is what may drive the human need to abandon and transcend a default mode of survival to cultivate altered states of consciousness? The idea is to approach this basic question in light of what arguably sets us apart in nature: human self-consciousness...
Behavioral Neuroscience
October 1, 2024
Dong-Hyun Youn, Cheolmin Jo, Jin Mook Kim et al.
1 citation
An N-protected methylenedioxymethamphetamine (MDMA), N-tert-butoxycarbonyl-3,4-methylenedioxymethamphetamine (t-BOC-3,4-MDMA), contains tert-butoxycarbonyl and can remain undetected in the illicit drug market. It is a new type of precursor substance that is not a chemical intermediate and can be converted into a controlled substance, MDMA, by deprotection of the N-tert-butoxycarbonyl group....
Contemporary Clinical Trials Communications
October 1, 2024
Erica Eaton, Christy Capone, Brian J Gully et al.
2 citations
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than either disorder alone, increased risk of suicide, and poorer response to existing treatments. A promising therapeutic intervention is the integration of 3,4-methylenedioxymethamphetamine (MDMA) and psychotherapy. The Food and Drug Administration (FDA)...
Reports of biochemistry & molecular biology
October 1, 2024
Salar Mahmoudi-Nejad, Isa Abdirad, Morteza Bagheri
3,4-methylenedioxymethamphetamine (MDMA) affects the male reproductive system. We investigated the mRNA levels of bax, bcl-2, and p53 genes in MDMA-induced apoptosis in mouse Sertoli (TM4) and Leydig (TM3) cells before and after taking Zinc. The TM3 and TM4 cells were cultured in four groups: I (untreated medium), II (medium with 5 mM MDMA), III (medium with 8 µM Zinc), and IV (medium with 8 µM...
Australian & New Zealand Journal of Psychiatry
October 1, 2024
Zohaib Nadeem, Stephen Parker, Hugh McGovern et al.
19 citations
Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses, the attitudes, knowledge and readiness of both mental health consumers and the general population remain largely unknown. A cross-sectional survey was conducted among Australians, targeting individuals with mental illness as potential mental health...
Clinical Pharmacology & Therapeutics
September 30, 2024
Andreas Halman, Rachel Conyers, Claire Moore et al.
13 citations
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these...
Neurorehabilitation
September 27, 2024
Walter Dunn, Anya K. Bershad, David E. Krantz et al.
2 citations
BACKGROUND: Neurorehabilitation in military populations is complicated by higher rates of PTSD and unique characteristics of military institutions. These factors can adversely impact the patient-therapist therapeutic alliance and engagement with the rehabilitation process leading to poorer outcomes. MDMA is a non-classical psychedelic with pro-social and fear regulating properties....
European Addiction Research
September 25, 2024
Ioanna A. Vamvakopoulou, David Nutt
13 citations
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid...
Neuroscience & Biobehavioral Reviews
September 20, 2024
Isabel Werle, Leandro J Bertoglio
17 citations
Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address these issues linked to anxiety/stress-related disorders effectively. This review identifies dose ranges associated with specific actions across various psychedelics. We examined psilocybin/psilocin, lysergic acid diethylamide (LSD),...
Science
September 19, 2024
Stacey B. Armstrong, Alan K. Davis
6 citations
There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have been combined with psychotherapy and studied in clinical trials in the United States and Europe. Psychedelics are hallucinogenic drugs that alter brain activity and facilitate altered states of consciousness. The...
Journal of Pharmacology and Experimental Therapeutics
September 18, 2024
Candace B Johnson, Donna Walther, Matthew J. Baggott et al.
5 citations
3,4-Methylenedioxymethamphetamine (MDMA) has shown efficacy as a medication adjunct for treating post-traumatic stress disorder (PTSD). However, MDMA is also used in nonmedical contexts that pose risk for cardiovascular and neurologic complications. It is well established that MDMA exerts its effects by stimulating transporter-mediated release of the monoamines 5-hydroxytryptamine (5-HT),...